家族性腺瘤性息肉病（familial adenomatous polyposis,FAP）是由APC（adenomatous polyposis coli）基因突变引起的常染色体显性遗传病。高脂血症作为FAP的肠外伴随症状逐渐被关注，同时在FAP的经典模型Apc基因突变的Min小鼠上也出现了高血脂症状。本文从高脂血症、FAP以及APC基因突变的角度，阐述三者的相互联系，期望对病人的预防与治疗提供有价值的参考。

FAP is an autosomal dominant disease caused by mutations of APC gene. Recently hyperlipidemia is thought as one of the extracolonic complications of FAP and the symptoms of hyperlipidemia have been seen in the classical FAP mouse model with Apc gene mutation. The relations among hyperlipidemia, FAP and APC gene mutation are discussed extensively in this review. The purpuse is to provide the valuable information for preventing and treating the FAP patients.

［1］Galiatsatos P, Foulkes WD.Familial adenomatous polyposis［J］. Am J Gastroenterol, 2006,101(2):  385-398.
［2］Mutoh M, Akasu T, Takahashi  M, et al. Possible involvement of hyperlipidemia in increasing risk of colorectal tumor development in human familial adenomatous polyposis［J］. Jpn J Clin Oncol, 2006, 36(3): 166-171.
［3］McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk?［J］. Cancer Epidemiol Biomarkers Prev, 1994, 3(8): 687-695.
［4］Groen EJ, Roos A, Muntinghe FL, et al.Extra-intestinal manifestations of familial adenomatous polyposis［J］. Ann Surg Oncol, 2008, 15(9): 2439-2450.
［5］Goss KH, Groden J.Biology of the adenomatous polyposis coli tumor suppressor［J］. J Clin Oncol, 2000,18(9):1967-1979.
［6］Cadigan KM, Nusse R.Wnt signaling: a common theme in animal development［J］. Genes Dev, 1997,11(24): 3286-3305.
［7］Morin PJ, Weeraratna AT. Wnt signaling in human cancer［J］. Cancer Treat Res, 2003,115(): 169-187.
［8］杨吉龙，王坚，周晓燕，等.侵袭性纤维瘤病中的APC和β-catenin基因及8号染色体异常［J］.中华肿瘤杂志，2008, 30(2): 116-120.
YANG Jilong, WANG Jian, ZHOU Xiaoyan, et al.Abnormalities of chromosome 8, APC and beta-catenin genes in aggressive fibromatosis［J］. Zhonghua Zhong Liu Za Zhi, 2008, 30(2): 116-120.
［9］Aoki K, Tamai Y, Horiike S, et al. Colonic polyposis caused by mTOR-mediated chromososmal instability in APC+/Delta716 Cdx2+/- compound mutant mice［J］. Nat Genet, 2003,35(4):323-330.
［10］Foulkes WD. A tale of four syndromes: familial adenomatous poly-posis, Gardner syndrome, attenuated APC and Turcot syndrome［J］. Qjm, 1995, 88(12): 853-863.
［11］Iwama T, Tamura K, Morita T, et al.  A clinical overview of familial adenomatous polyposis derived from the database of the polyposis registry of Japan［J］. Int J Clin Oncol, 2004,9(4): 308-316.
［12］Niho N, Takahashi  M, Kitamura  T, et al. Concomitant  suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands［J］. Cancer Res, 2003, 63(18): 6090-6095.
［13］Cucuianu M, Coca M, Hancu N, et al. Reverse cholesterol transport and atherosclerosis. A mini review［J］. Rom J Intern Med, 2007, 45(1): 17-27.
［14］Agarwal B, Rao CV, Bhendwal S, et al.Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac［J］. Gastroenterology, 1999, 117(4): 838-847.
［15］Niho N, Mutoh  M,Takahashi M, et al. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice［J］. Proc Natl Acad Sci U S A, 2005, 102(8): 2970-2974.
［16］Barton TP, Cruse JP, Lewin MR,et al. Changes in serum lipids related to the presence of experimental colon cancer［J］. Br J Cancer, 1987, 56(4): 451-454.
［17］Femia AP, Caderni G. Rodent models of colon carcinogenesis for the study of chemopreventive activity of natural products［J］. Planta Med, 2008, 74(13):1602-1607.
［18］Mutoh M,Niho  N, Komiya  M, et al. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice［J］. Carcinogenesis, 2008, 29(4): 824-829.
［19］Kortlever RM, Higgins PJ, Bernards R, et al. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence［J］. Nat Cell Biol, 2006, 8(8): 877-884.
［20］Bahia L, Aguiar LG, Villela N, et al.  Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome［J］. Clinics, 2006, 61(5): 433-440.
［21］Yu J, Chu ES, Hui AY,et al.  Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis［J］. Biochem Biophys Res Commun, 2007, 356(1): 53-59.
［22］Eisinger AL,Nadauld LD, Shelton DN, et al. The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid［J］. J Biol Chem, 2006, 281(29): 20474-20482.
［23］Bonaterra GA, Hildebrandt W, Bodens A, et al. Increased cyclooxygenase-2 expression in  peripheral blood mononuclear cells of smokers and hyperlipidemic subjects［J］. Free Radic Biol Med, 2005, 38(2): 235-242.